June 1, 2018
Novartis’s first targeted migraine prevention therapy to patients in Europe
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Novartis’s Aimovig…
Pharmaceuticals, Biotechnology and Life Sciences
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Novartis’s Aimovig…
The US Food and Drug Administration (FDA) has approved Novartis’s and Amgen’s Aimovig (erenumab) for the preventive treatment of migraine in…
Amgen’s Phase 3b study called Liberty, in co-development with Novartis, aimed to test Aimovig for treating migraine, has met it’s…